renal denervation
Capricor Plunges 67% on FDA Panel News Ahead of DMD Vote
Capricor Therapeutics lost roughly two-thirds of its market value on Monday. Not from a failed trial. From a document explaining what a panel might discuss on Wednesday. Curis and Autonomix Medical had smaller, quieter reactions of their own to their own news this week, one up, one down, each worth understanding on its own terms.…

